Comparative Pharmacology
Head-to-head clinical analysis: SULLA versus THIOSULFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULLA versus THIOSULFIL.
SULLA vs THIOSULFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
Thiosulfil (sulfamethizole) is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis and thereby nucleic acid production.
100 mg orally once daily, increased to 200 mg daily if needed.
500 mg orally twice daily for 10-14 days.
None Documented
None Documented
6-12 hours; prolonged in renal impairment (up to 30 hours)
Terminal elimination half-life is 2-4 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Renal: 70-90% as unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic